Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to “Buy” at Wall Street Zen

Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday.

Other analysts also recently issued research reports about the company. Wells Fargo & Company upped their price target on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research note on Monday, January 5th. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, January 5th. Jefferies Financial Group restated a “hold” rating and issued a $3.70 target price on shares of Ironwood Pharmaceuticals in a report on Thursday, February 26th. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Craig Hallum raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.93.

Ironwood Pharmaceuticals Stock Down 3.6%

Shares of IRWD opened at $3.49 on Friday. The firm has a market cap of $567.75 million, a price-to-earnings ratio of 26.85 and a beta of 0.24. The company’s fifty day moving average is $4.32 and its 200-day moving average is $2.91. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). The business had revenue of $47.71 million during the quarter, compared to the consensus estimate of $86.10 million. Ironwood Pharmaceuticals had a negative return on equity of 13.72% and a net margin of 8.11%. As a group, research analysts predict that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,406 shares during the last quarter. LSV Asset Management acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter worth $30,000. Captrust Financial Advisors bought a new position in Ironwood Pharmaceuticals during the second quarter worth $32,000. Jump Financial LLC bought a new position in Ironwood Pharmaceuticals during the fourth quarter worth $34,000. Finally, DGS Capital Management LLC acquired a new position in Ironwood Pharmaceuticals during the 4th quarter valued at $35,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.